Quantitative Clinical Reasoning Flashcards

A clinical trial reports: Treatment reduces mortality from 4% to 2% (RRR 50%, ARR 2%, NNT 50, p<0.001). A health policy analyst says: 'This is a major treatment advance.' A skeptic says: 'NNT 50 is too high to matter.' Who is MORE quantitatively correct?

Answer: Neither is fully correct — the clinical value depends on outcome severity, treatment cost, harm profile, and patient preferences; NNT alone cannot determine policy

NNT must be interpreted in context. A mortality endpoint is high-value; NNT of 50 may or may not be policy-relevant depending on costs, harms, and alternatives.

A clinical pharmacist calculates the loading dose for a patient using: Loading Dose = (Target Concentration × Volume of Distribution) / Bioavailability. If target Cp = 10 mg/L, Vd = 40 L, and bioavailability = 0.80 (oral), what is the correct loading dose?

Answer: 500 mg

Loading dose = (10 × 40) / 0.80 = 400 / 0.80 = 500 mg.

A study reports a hazard ratio (HR) of 0.65 (95% CI: 0.50–0.85) for mortality in the treatment group. Which quantitative interpretation is MOST accurate?

Answer: The treatment group experienced 35% lower instantaneous risk of mortality at any given time compared to controls, with confidence the true HR lies between 0.50 and 0.85

A hazard ratio of 0.65 indicates a 35% reduction in the instantaneous risk of mortality. The CI (0.50–0.85) does not include 1.0, confirming statistical significance.

A diagnostic laboratory reports: Creatinine clearance = 35 mL/min for a patient. The pharmacist needs to determine if this qualifies as moderate renal impairment (CrCl 30–59 mL/min). The CrCl was calculated using the Cockcroft-Gault equation. Which quantitative consideration is MOST important before making a dosing decision?

Answer: The Cockcroft-Gault equation was derived from a specific population; the estimated CrCl has inherent imprecision (±20%), so CrCl of 35 could plausibly represent Stage 2 or Stage 3b CKD — the borderline value warrants clinical correlation

Cockcroft-Gault CrCl estimates have inherent variability of ±15–20%; a borderline value like 35 mL/min requires clinical correlation rather than mechanical dosing adjustment.

In a study of 500 patients, a new hemostasis agent reduced mean surgical blood loss from 850 mL to 720 mL (SD = 220 mL in both groups). Which quantitative measure BEST helps determine if this 130 mL reduction is clinically meaningful?

Answer: Cohen's d effect size — the standardized difference indicates whether the reduction is large relative to natural variation in blood loss

Cohen's d standardizes the difference against within-group variability (SD=220), revealing whether 130 mL represents a meaningful or trivial departure from natural variation.

A hospital reports it administered the correct dose of vancomycin in 94% of cases audited. The hospital's target is 95%. A quality officer calls this a 'minor gap.' Which quantitative perspective challenges this characterization?

Answer: If the hospital administers 200 vancomycin doses per week, a 1% error rate represents 2 dosing errors per week — approximately 104 per year with potential for nephrotoxicity or therapeutic failure

Translating percentage error rates into absolute numbers reveals the clinical magnitude: 1% of 200 doses/week = 2 errors/week = 104/year, each with potential for harm.